Bharat Biotech, IHH Healthcare collaborate to provide Covaxin at Gleneagles Global Hospitals
The partnership acts as a focused approach to serve communities across Bengaluru, Chennai, Hyderabad, and the rest of the cities within the network of hospitals.
Kuala Lumpur: IHH Healthcare Bhd has entered into a partnership with Indian biotechnology company Bharat Biotech to provide Covaxin at its Gleneagles Global Hospitals in three locations in India.
According to news portal The Hindu Business Line, the global healthcare provider has three healthcare institutions in India, namely BGS Gleneagles Global Hospital in Kengeri, Bengaluru; Gleneagles Global Health City in Chennai; and Gleneagles Global Hospitals in Hyderabad.
"Three of the IHH Healthcare institutions in India will foray into this initiative and also widen the vaccination drive for the younger population," the group said in an article on the news portal.
The partnership comes after the Indian government's announcement of a liberalised and accelerated phase three strategy of Covid-19 vaccination drive from May.
The partnership also acts as a focused approach to serve communities across Bengaluru, Chennai, Hyderabad, and the rest of the cities within the network of hospitals.
Meanwhile, IHH Healthcare India CEO Shriram Vijayakumar said in a statement that apart from the vaccination drive at its hospitals, the group's focus is also to include larger communities through its Corporate Vaccination Programme and camps at residential complexes.
The healthcare group added it will continue to provide Covid-19 vaccine to people in the age group of 45-plus through the government-subsidised vaccination scheme.
At the time of writing, shares of IHH Healthcare traded three sen or 0.57% lower at RM5.23, giving it a market capitalisation of RM45.92 billion.